Season 9 · Episode 11
S9 Ep11: FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
OncLive® On Air · OncLive® On Air
July 17, 202313m 39s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.